Utility Values From Pooled Analysis of High Concentration (179 mg) Capsaicin Patch (HCCP) Studies In Peripheral Neuropathic Pain (PNP)
Author(s)
Rita Freitas1, Charlotte BOTH, PhD2, Gerlinde Dahmen, PhD3, Cerian Reynish, PhD4.
1Global HEOR Lead, Grunenthal, Lisboa, Portugal, 2Grunenthal GmBH, Aachen, Germany, 3Numerus AG, Reutlingen, Germany, 4Numerus Ltd, Wokingham, United Kingdom.
1Global HEOR Lead, Grunenthal, Lisboa, Portugal, 2Grunenthal GmBH, Aachen, Germany, 3Numerus AG, Reutlingen, Germany, 4Numerus Ltd, Wokingham, United Kingdom.
OBJECTIVES: To estimate health state utility values that capture the quality-of-life impact by pain severity level.
METHODS: EQ-5D data were pooled from five PNP studies: ASCEND, PACE, STEP, STRIDE (3-level) and ELEVATE (5-level). Pain severity was measured using numerical rating scales (NRS) and categorized into four health states: no pain (score = 0), mild (1-3), moderate (4-6), and severe (7-10). Utility scores were derived using the UK-specific value set, applying Dolan and crosswalk methods. All pain scores between date of EQ-5D assessment and up to seven days were included, regardless of treatment arm and assessment timing. Descriptive statistics were calculated for each pain category.
RESULTS: A total of 10,079 observations from 2,114 participants were included in the pooled analysis. Mean (SD) EQ-5D utility scores by pain category were:
CONCLUSIONS: This pooled analysis of clinical trials provides robust utility estimates that capture the quality-of-life impact of different pain severities in PNP. The clear separation between pain-defined utility states highlights the substantial impact of even moderate pain on patient quality of life and supports the relevance of pain-defined health states in health economic evaluations.
METHODS: EQ-5D data were pooled from five PNP studies: ASCEND, PACE, STEP, STRIDE (3-level) and ELEVATE (5-level). Pain severity was measured using numerical rating scales (NRS) and categorized into four health states: no pain (score = 0), mild (1-3), moderate (4-6), and severe (7-10). Utility scores were derived using the UK-specific value set, applying Dolan and crosswalk methods. All pain scores between date of EQ-5D assessment and up to seven days were included, regardless of treatment arm and assessment timing. Descriptive statistics were calculated for each pain category.
RESULTS: A total of 10,079 observations from 2,114 participants were included in the pooled analysis. Mean (SD) EQ-5D utility scores by pain category were:
- No pain: 0.827 (0.238), n = 337
- Mild pain (1-3): 0.716 (0.188), n = 2,508
- Moderate pain (4-6): 0.591 (0.226), n = 4,562
- Severe pain (7-10): 0.353 (0.330), n = 2,672
CONCLUSIONS: This pooled analysis of clinical trials provides robust utility estimates that capture the quality-of-life impact of different pain severities in PNP. The clear separation between pain-defined utility states highlights the substantial impact of even moderate pain on patient quality of life and supports the relevance of pain-defined health states in health economic evaluations.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO263
Topic
Clinical Outcomes, Economic Evaluation
Topic Subcategory
Clinical Outcomes Assessment
Disease
Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)